APA (7th ed.) Citation

Alyautdin, R. N., Romanov, B. K., Pereverzev, A. P., Chikalo, A. O., Bunyatyan, N. D., Merkulov, V. A., & Mironov, A. N. (2018). Alipogene tiparvovec: A long journey of risk-benefit ratio assessment of gene therapy products. Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’).

Chicago Style (17th ed.) Citation

Alyautdin, R. N., B. K. Romanov, A. P. Pereverzev, A. O. Chikalo, N. D. Bunyatyan, V. A. Merkulov, and A. N. Mironov. Alipogene Tiparvovec: A Long Journey of Risk-benefit Ratio Assessment of Gene Therapy Products. Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’), 2018.

MLA (9th ed.) Citation

Alyautdin, R. N., et al. Alipogene Tiparvovec: A Long Journey of Risk-benefit Ratio Assessment of Gene Therapy Products. Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’), 2018.